Ensho Therapeutics reposted this
We are pleased to share that EA Pharma Co., Ltd. has entered into an exclusive worldwide license agreement with Ensho Therapeutics, Inc. This agreement allows Ensho Therapeutics to develop, manufacture, and commercialize EA1080, a novel treatment for inflammatory bowel disease (IBD), outside Japan and certain Asian regions. Ensho Therapeutics, established to further develop EA1080, brings together a team with extensive experience in global IBD treatment development. Through this collaboration, EA Pharma and Ensho Therapeutics aim to improve the quality of life for 5 million IBD patients worldwide. Under the terms of the agreement, Ensho Therapeutics has already prepared a clinical development strategy, and aims to commence Phase 2 clinical development in the first half of 2025. We believe this partnership will have major impact on the immunology and inflammatory disease areas, and contribute to healthier life for humanity globally. For more details, see the press releases below: Ensho Therapeutics: https://lnkd.in/gBYMm5uG EA Pharma (Japanese only): https://lnkd.in/gAyZTjRa #WeAreAjinomotoGroup #Innovation #WellBeing #Collaboration #Research EA Pharma: was established in April 2016 by integration of gastrointestinal business unit of Eisai Group and gastrointestinal business unit of the Ajinomoto Group, and its currently as a subsidiary of Eisai Group.